BridgeMD
New treatment option for Osteoporosis Risk
Official title Comparison of Bone Microarchitecture Analysed by HRpQCT and pQCT in Pathologies With Bone Loss and/or Muscle Loss
ClinicalTrials.gov ID: NCT06541548
What this study is testing
- What it's testing
- The study aims to utilize medical devices, such as the Xtreme CT and XCT 3000, to assess bone and muscle microarchitecture for various pathologies. The devices provide crucial data on bone and muscle density, aiding in understanding fracture risks associated with conditions like rheumatoid arthritis and neurological disorders.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- For the patients: Women or men treated at the Saint-Etienne University Hospital and presenting an osteoporotic risk with one of the following...
- Osteoporosis defined by: History of a documented brittle bone fracture
- Bone fragility: Patient with indication for bone densitometry but no history of fracture
- Inflammatory joint disease:
- Rheumatoid arthritis
You likely can't join if
- No sign written consent For the controls:
- Medications inducing bone loss:
- anti-aromasin or GnRH agonist for at least 6 months,
- corticosteroids (dose ≥ 5 mg/d for 6 months)
- anti-epileptic drugs: carbamazepine, phenobarbital, phenytoin, primidone, valproic acid for at least 6 months)
- History of fracture due to bone fragility
See the full eligibility criteria
- For the patients: Women or men treated at the Saint-Etienne University Hospital and presenting an osteoporotic risk with one of the following associated pathologies:
- Osteoporosis defined by: History of a documented brittle bone fracture
- Bone fragility: Patient with indication for bone densitometry but no history of fracture
- Inflammatory joint disease:
- Rheumatoid arthritis
- Spondyloarthritis
- Chronic kidney disease
- Endocrinopathies:
- Primary hyperparathyroidism
- Constitutional thinness
- Anorexia nervosa
- Obesity (BMI \>30)
- Sarcopenia
- Neuropathies - Parkinson's disease For the controls: Acute episode of spinal or radiculalgia (less than one month old) with corticosteroid treatment of less than 1 month Signature of written consent
- No sign written consent For the controls:
- Medications inducing bone loss:
- anti-aromasin or GnRH agonist for at least 6 months,
- corticosteroids (dose ≥ 5 mg/d for 6 months)
- anti-epileptic drugs: carbamazepine, phenobarbital, phenytoin, primidone, valproic acid for at least 6 months)
- History of fracture due to bone fragility
- Taking bone-targeting medication (biphosphonate, teriparatide, strontium ranelate)
The study team makes the final eligibility decision.
Where it's taking place
- Saint-Etienne, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Saint-Etienne, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.